Immunity27 Jun 2020 09:17
The immunity subject is shrouded in secrecy because Govs need a compliant population to adhere to regulations. They don’t want a population that’s difficult to control, ie a large percentage refusing to adhere to rules because they are immune. They need the data from mass antibody testing. They don’t want the rebellious consequences of those who test positive refusing to socially distance or refusing to go back into lockdown if required.
Rather than rubbish posted by traders on here, if you want to know what the scientists findings are on immunity then read the key findings at the end of the scientific paper I posted on the 14th. Here it is again.....
Coronavirus antibody immunity scientific paper14 Jun 2020 06:57
“A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease“
“Key findings:
We have presented a broad, comprehensive review of multiple aspects of the literature on antibody immunity to coronaviruses. We identified a number of key findings. The median time to detection was similar across different antibodies for SARS-CoV-1 (12 days; IQR 8-15.2 days) and SARS-CoV-2 (11 days; IQR 7.25-14 days), but longer for MERS-CoV (16 days; IQR 13-19 days). Most long-term studies found that IgG waned over time (typically detectable up to at least a year) while others found detectable levels of IgG three years post symptoms onset. Antibody kinetics varied across the severity gradient with longer durations of detectable antibody associated with more severe symptoms. Human challenge studies with HCoV indicate that serum and mucosal immune responses (serum IgG, IgA, neutralizing titer, mucosal IgA) provide possible correlates of protection from infection and disease. However, repeat human challenge experiments with single HCoV suggest individuals can be infected with the same HCoV one year after first challenge, but with possible lower severity. There is cross-reactivity within but minimal reactivity between Alpha- and Beta-CoVs. While endemic HCoVs rarely induce cross-reactive antibodies against emerging HCoVs, SARS-CoV-1 and MERS-CoV stimulate antibodies induced by prior HCoV infections.”
https://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.full.pdf
Sign In
Follow the stocks
